Summary: The United States Food and Drug Administration has issued emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children. This authorization came just two days after an interim analysis of the NIAID-sponsored Adaptive COVID-19 Treatment Trial (ACTT) showed patients receiving remdesivir had a 31% reduced time to recovery compared to patients receiving placebo (p<0.001).
Information current as of 05/01/2020
Organization: Food and Drug Administration (FDA)
Title: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
Web Link: Read more here!